Rapid, durable, and significant reductions in splenomegaly with JAKAVI, regardless of JAK2V617F mutation status1
Significant reduction in spleen volume throughout the 48-week study period and 3-year follow-up1,2
Adapted from: Harrison C et al. N Engl J Med. 2012;366:787-798.1
- 51% of patients treated with JAKAVI (75/146) achieved ≥35% reduction in spleen volume at any time during the 3-year follow-up2
Significant reduction in splenomegaly regardless of JAK2V617F mutation status1,3
Adapted from: Harrison C, Kiladjian J-J, Barosi G; for the COMFORT-II authors. Ruxolitinib for myelofibrosis [letter]. N Engl J Med. 2012;366(21):2032-2034.3
Based on a post hoc analysis.
- 97% of patients treated with JAKAVI (132/136) achieved any reduction in spleen volume at any time during the 48-week study period, while a majority of patients in the BAT arm progressively worsened1*
Significant spleen reductions sustained at 3-year follow-up2
Adapted from: Cervantes F et al. Blood. 2013;122:4047-4053.2
Based on a prespecified exploratory endpoint. JAKAVI included both randomised and extension phases; BAT included randomised phase only and did not include assessments after crossover.
- Median time to ≥35% reduction in spleen volume was as early as 12 weeks1
- Kaplan-Meier estimated probabilities of maintaining a ≥35% reduction in spleen volume at Weeks 48 and 144 were 73% (95% CI: 61-82) and 50% (95% CI: 36-63), respectively2
JAKAVI Treatment in Clinical Practice: Treating splenomegaly in a patient with high disease burden but low IPSS risk
The IPSS is an effective tool to predict survival time; however, it may not account for the impact of MF-related symptoms, including splenomegaly. Watch the video below to learn more from Dr Claire Harrison on treating splenomegaly in patients with MF.